One- to three-year outcome for 14 neonatal survivors of extracorporeal membrane oxygenation.
Extracorporeal membrane oxygenation, using venoarterial or venovenous perfusion, is a safe and effective procedure in the term of near-term infant with life-threatening respiratory failure. Without extracorporeal membrane oxygenation, due to the severity of their disease, these children are at high risk for neurologic damage, chronic lung disease, and death. Because survival is not expected without extracorporeal membrane oxygenation therapy, there is no corresponding control group to which these survivors may be compared. In this report, we reviewed the outcome at 1 to 3 years in the first 14 survivors of extracorporeal membrane oxygenation treated at our institution. Seven of 14 neonatal extracorporeal membrane oxygenation survivors (50%) were normal or near normal at between 1 and 3 years of age. Ten (71%) had normal mental ability. We conclude that in neonates with high mortality risk from respiratory failure, near-normal growth and development can be expected in the majority who survive with extracorporeal membrane oxygenation treatment.
D002543:Cerebral Hemorrhage / Q000209:etiology; D002658:Developmental Disabilities / Q000209:etiology; D004569:Electroencephalography; D005112:Extracorporeal Circulation; D005260:Female; D005500:Follow-Up Studies; D006128:Growth; D006801:Humans; D007231:Infant, Newborn; D007361:Intelligence Tests; D008297:Male; D010107:Oxygenators, Membrane / Q000009:adverse effects; D012127:Respiratory Distress Syndrome, Newborn / Q000628:therapy*; D012306:Risk; D014043:Tolazoline / Q000627:therapeutic use
D014043:Tolazoline